Last reviewed · How we verify
An Open-Label Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis
The purpose of this research study is to better understand how fluocinonide cream 0.1% (Vanos®) works when people use it to treat atopic dermatitis for just a few days.
Details
| Lead sponsor | Wake Forest University Health Sciences |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 20 |
| Start date | 2009-03 |
| Completion | 2009-10 |
Conditions
- Atopic Dermatitis
Interventions
- Fluocinonide Cream 0.1%
Primary outcomes
- Change in Investigator Global Assessment of Atopic Dermatitis Severity From Baseline to Day 2/3. — Baseline to 3 days
Use of the Investigator's Global Assessment (IGA) score, a subjective scale measuring disease severity. Based on a 6-point scale from 0 (completely clear) to 5 (very severe). Defined score of 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe.
Countries
United States